

MINUTES

Drug Formulary Committee

8/29/2017

Committee members present were: Bill Wheeler, Eric Strauss, Cindy Zimmerman, Maralyn Lytle, Misty Knight, Adrienne McLean, Bri Lake, Julia Brennan, Kristine Ediger, Karen Wiles, Jennifer Hepfner, Lindi Mandy, Michelle Fairclough, Lance Zanto, Doug Buman and Tony King.

Other's present: Don Judge (LMAC), Ken Eichler (Work Loss Data)

Members attending via GoToMeeting were: Mike Marsh, Dr. John Schumpert, Becky Curtis, and Leslae Dalpaiz.

Other's online: John Nelson, Adam Fowler, Carlos Luna (Reed Group), and Trey Gillespie.

Bill Wheeler opened with a discussion about a condition based formulary list eg. ACOEM, which would be hard to navigate and would require an internal P&T committee to assist with complicated updates. All three of the formularies presented, ODG, ACOEM, and WA state, would have something free to offer. Which of the three would be the easiest to implement into the current MT guidelines.

Members present and online commented and asked questions and asked many questions regarding the various formularies and many specific to ODG. Some responded favorably to ODG, others felt more information was needed prior to making a decision.

Bill Wheeler discussed the topic of transparency with ACOEM and ODG, and it was agreed upon all three choices lack some transparency.

Bri Lake has reached out to NCCI for cost frequency estimates data and will be looking into other states as to how they handle specifics such as dispute resolution processes, legacy claims, prior authorization, etc.

Bill Wheeler closed the meeting with the Department's recommendation for ODG, for ease of use, least amount of administrative cost in implementation, and ease of keeping current MT Guidelines with little modification.

The next meeting will be scheduled at a later date to revisit.